ArticleEuropean journal of nuclear medicine and molecular imaging2025
Comparisons of treatment performance and therapy sequences in neuroendocrine neoplasms using progression-free survival ratios.
Article in European journal of nuclear medicine and molecular imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Patient characteristics and prognostic factors in advanced treatment lines in metastatic neuroendocrine tumors.Journal of endocrinological investigation · 2026Article
- Systemic therapy for gastroenteropancreatic neuroendocrine neoplasms: current landscape and future directions.Therapeutic advances in medical oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionOptimal sequencing of therapies is an important unresolved issue in metastatic neuroendocrine neoplasms (NEN). Progression-free survival (PFS) ratios constitute a potential method for intra-patient treatment comparisons and were used in this analysis to assess the relative treatment benefit of established therapies.
methodsThis retrospective study included NEN patients of the Medical University of Vienna (treated in 2010-2024) who had metastatic disease and had received ≥ 2 palliative systemic therapies. The primary objective was the calculation of PFS ratios for therapy sequences, with the PFS ratio defined as the proportion of PFS2 (subsequent treatment) and PFS1 (prior treatment).
resultsOf the 177 patients included, 104 had neuroendocrine tumors (NET) G1/G2, 16 NET G3, 28 lung/thymic carcinoids, and 29 a neuroendocrine carcinoma (NEC). In terms of treatment sequence, SSA was the most common first-line treatment in NET G1/G2 and thoracic carcinoids (n = 84), frequently followed by PRRT (n = 60), everolimus (n = 13), and treatments grouped as 'other' (n = 9). After platinum/etoposide in NEC (n = 26), FOLFOX/FOLFIRI (n = 13), CAPTEM (n = 3), and 'other' therapies (n = 9) were second-line therapies. The median PFS ratio for PRRT after first-line SSA was 1.86, for everolimus 0.99, and for 'other' treatments 0.59 (p = 0.004). Following platinum/etoposide, FOLFOX/FOLFIRI had a median PFS ratio of 0.46. In subgroup analyses according to primary localization, everolimus led to disproportionately long PFS intervals following SSA/PRRT in lung/thymic carcinoids, whereas therapies after PRRT exhibited relatively low PFS ratios in enteropancreatic NET.
conclusionsPFS ratios accommodate the heterogeneity of NEN and can provide insights regarding treatment performance and treatment sequencing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.